Last reviewed · How we verify
rTG
rTG is a recombinant human tissue transglutaminase used as a therapeutic enzyme to cross-link and stabilize proteins in wound healing and tissue repair applications.
rTG is a recombinant human tissue transglutaminase used as a therapeutic enzyme to cross-link and stabilize proteins in wound healing and tissue repair applications. Used for Hemostasis and wound healing in surgical applications, Topical tissue adhesion and repair.
At a glance
| Generic name | rTG |
|---|---|
| Also known as | re-esterified triglycerides |
| Sponsor | Gottfried Wilhelm Leibniz Universität Hannover |
| Drug class | Enzyme (tissue transglutaminase) |
| Target | Tissue transglutaminase (TG2/TGM2) |
| Modality | Small molecule |
| Therapeutic area | Wound Care / Hemostasis / Surgery |
| Phase | FDA-approved |
Mechanism of action
Tissue transglutaminase (TG) catalyzes the formation of covalent cross-links between proteins by creating isopeptide bonds, which strengthens tissue structure and promotes hemostasis. The recombinant form (rTG) is derived from human sources and applied topically or locally to enhance wound closure, tissue adhesion, and hemostatic control in surgical and traumatic settings.
Approved indications
- Hemostasis and wound healing in surgical applications
- Topical tissue adhesion and repair
Common side effects
- Local inflammatory response
- Allergic reaction
Key clinical trials
- A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo (PHASE3)
- Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder (PHASE2)
- Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis
- An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (PHASE3)
- Ultrasound-assisted Versus Real-time Ultrasound-guided Combined Spinal-epidural Anesthesia in Elderly Patients (NA)
- Dopaminergic Therapy for Frontotemporal Dementia Patients (PHASE2)
- Comparison of the Efficacy of Conventional Landmark, Ultrasound-Assisted, and Real-Time Ultrasound-Guided Techniques in Spinal Anesthesia for Obese Patients (NA)
- XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rTG CI brief — competitive landscape report
- rTG updates RSS · CI watch RSS
- Gottfried Wilhelm Leibniz Universität Hannover portfolio CI